Tandem Diabetes Care Beats Q4 Earnings Estimates

The medical device company reported a smaller-than-expected loss per share for the quarter.

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

Tandem Diabetes Care (NASDAQ:TNDM), a medical device company focused on insulin delivery systems, announced its Q4 2025 earnings results on Thursday. The company reported a loss of $0.01 per share, beating analysts' consensus estimate of a $0.06 loss per share. Tandem Diabetes Care also reported revenue of $290.38 million for the quarter, exceeding the $277.14 million expected by analysts.

Why it matters

Tandem Diabetes Care's better-than-expected financial performance in Q4 2025 suggests the company's insulin delivery products are continuing to gain traction with customers. As a leading player in the insulin pump market, Tandem's results are closely watched by investors and industry analysts.

The details

For the quarter, Tandem Diabetes Care reported a loss of $0.01 per share, beating the consensus estimate of a $0.06 loss per share. The company's revenue of $290.38 million also exceeded the $277.14 million expected by analysts. Tandem attributed the stronger-than-expected results to growing demand for its flagship t:slim X2 insulin pump, which features integrated continuous glucose monitoring capabilities.

Tandem Diabetes Care reported its Q4 2025 earnings results on Thursday, February 19, 2026.

The players